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Abstract: 
Aims: Patients hospitalized at the time of human immunodeficiency virus-associated 
tuberculosis (HIV-TB) diagnosis have high early mortality. We hypothesized that 
compared to outpatients, there would be lower antituberculosis drug exposure in 
hospitalized HIV-TB patients, and amongst hospitalized patients exposure would be 
lower in patients who die or have high lactate (a sepsis marker).  
Methods: We performed pharmacokinetic sampling in hospitalized HIV-TB patients 
and outpatients. Plasma rifampicin, isoniazid and pyrazinamide concentrations were 
measured in samples collected predose and at 1, 2.5, 4, 6 and 8 hours on the third 
day of standard antituberculosis therapy. Twelve-week mortality was ascertained for 
inpatients. Noncompartmental pharmacokinetic analysis was performed. 
Results: Pharmacokinetic data was collected in 59 hospitalized HIV-TB patients and 
48 outpatients. Inpatient twelve-week mortality was 11/59 (19%). Rifampicin, 
isoniazid and pyrazinamide exposure was similar between hospitalized and 
outpatients (Cmax:7.4 vs. 8.3 μg·mL-1, p=0.223; 3.6 vs. 3.5 μg·mL-1, p=0.569; 50.1 vs. 
46.8 μg·mL-1, p=0.081; AUC0-8:41.0 vs. 43.8 mg·h·L-1, p= 0.290; 13.5 vs. 12.4 
mg·h·L-1, p=0.630; 316.5 vs. 292.2 mg·h·L-1, p=0.164, respectively) and not lower in 
inpatients who died. Rifampicin and isoniazid Cmax were below recommended ranges 
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in 61% and 39% inpatients and 44% and 35% outpatients. Rifampicin exposure was 
higher in patients with lactate >2.2mmol·L-1. 
Conclusion: Mortality in hospitalized HIV-TB patients was high. Early antituberculosis 
drug exposure was similar to outpatients and not lower in inpatients who died. 
Rifampicin and isoniazid Cmax were sub-optimal in 61% and 39% of inpatients and 
rifampicin exposure was higher in patients with high lactate. Treatment strategies 
need to be optimized to improve survival. 
 
What is already known about this subject: 
 Patients hospitalized with human immunodeficiency virus associated 
tuberculosis (HIV-TB) have high mortality despite treatment and often present 
with a clinical picture compatible with sepsis. 
 Deaths occur early and there is paucity of data regarding antitubercular drug 
exposure in hospitalized critically ill HIV-TB patients. 
What this study adds:  
 Rifampicin, isoniazid and pyrazinamide exposure in hospitalized HIV-TB 
patients and outpatients on day three of standard treatment are described. 
 Hospitalized HIV-TB patients do not have lower exposure than outpatients, 
however many have sub-optimal concentrations which could play a role in 
mortality. 
 This could inform treatment strategies in hospitalized HIV-TB patients.  
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Introduction 
Tuberculosis (TB) is the leading cause of hospitalization and in-hospital death in 
human immunodeficiency virus (HIV)-infected people worldwide [1 2]. In high-burden 
settings hospitalized patients with HIV-associated tuberculosis (HIV-TB) have case 
fatality rates between 11% and 32% [3-8]. The majority of these deaths occur within 
2 weeks [3-5 8] and in post mortem series inpatient HIV-TB deaths are reported at a 
median of 4-5 days after admission [9 10] , with 50% of deaths occurring in patients 
already on antituberculosis therapy [11]. 
Severe HIV-TB may present with clinical features of bacterial sepsis [12-14]. In high-
burden settings Mycobacterium tuberculosis bloodstream infection (MTB BSI) is the 
most common diagnosis in HIV-infected patients presenting to hospital with a clinical 
syndrome of sepsis [15-18]. Analogous to sepsis there are many factors in severe 
HIV-TB which could reduce drug exposure, such as impaired absorption of orally 
administered drugs due to delayed gastric emptying and decreased perfusion of the 
gastrointestinal tract, increased volume of distribution due to fluid shifts, and 
augmented renal clearance [19 20]. Other factors in advanced HIV-infection such as 
intestinal tuberculosis, HIV-related enteropathy, and gastro-intestinal opportunistic 
infections and macro- or micronutrient deficiencies [21-23] could contribute to 
reduced drug exposure. Limited existing data suggest that antitubercular drug 
exposure in critically ill patients is inadequate [24]. Elevated blood lactate is used as 
a marker of sepsis severity [25] and is associated with mortality in hospitalized 
patients with HIV-TB [5].  
HIV infection has a variable effect on antituberculosis drug concentrations across 
studies, with some studies showing lower concentrations than in HIV-negative 
patients [26-28]. There are few pharmacokinetic studies in HIV-TB which assess 
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relationships between drug exposure and clinical outcomes [29-31]. 
Rifampicin is a potent inducer of drug metabolizing liver enzymes [32] and also 
undergoes auto-induction [33]. The majority of rifampicin pharmacokinetic studies 
have been performed after administration of multiple doses when autoinduction is 
advanced [27], yet mortality in hospitalized HIV-associated tuberculosis patients 
occurs early. In the parent cohort of this PK study 37% of deaths occurred within 
seven days of enrolment [34]. Preliminary evidence suggest that higher-dose than 
the currently recommended 10 mg kg-1 daily may improve survival in HIV-TB patients 
with low CD4 counts [35]. 
We performed intensive pharmacokinetic (PK) studies on the third day of 
antituberculosis therapy, administered at standard doses, in hospitalized patients 
with HIV-TB and outpatient controls and determined 12-week mortality in 
hospitalized patients. We compared exposure of rifampicin, isoniazid and 
pyrazinamide between inpatients and outpatients; between inpatients who survived 
and those who died within 12 weeks, and between inpatients presenting with an 
elevated lactate (a marker of sepsis severity) and those presenting with a normal 
lactate. We hypothesized that exposure to rifampicin, isoniazid and pyrazinamide 
would be lower in inpatients than outpatients; lower in inpatients who died within 12 
weeks compared to survivors, and lower in inpatients presenting with elevated 
venous lactate compared to those presenting with normal lactate. 
 
Methods 
Study Design and Study population 
We enrolled hospitalized HIV-infected adults with a CD4 count of ≤350 cells μl-1 
starting treatment for active tuberculosis at Khayelitsha Hospital and ambulant 
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outpatients (HIV-infected and uninfected) at Ubuntu clinic, Site B Khayelitsha, Cape 
Town, South Africa between November 2014 and November 2016. Inpatients were 
recruited as part of an observational cohort study investigating causes of mortality in 
hospitalized patients with HIV-TB. HIV-infected adults aged 18 years or older, with a 
suspected new diagnosis of tuberculosis were enrolled at presentation to hospital 
and PK studies were performed in a sub-group within the routine hospital service on 
the third day of antituberculosis therapy. Patients who survived to the third day of 
tuberculosis treatment were enrolled sequentially for PK studies, provided they still 
required inpatient care, did not require transfer to a tertiary care facility for intensive 
care or investigations and there were adequate staff to fulfill the parent study’s 
operational requirements and perform PK study. Outpatients were enrolled at 
treatment initiation and returned for PK studies on the third day of therapy. Patients 
were enrolled regardless of antiretroviral therapy status or type. Outpatients were 
HIV-infected or HIV-uninfected. Clinical data and baseline blood tests were obtained 
at enrolment. Twelve-week vital status was ascertained for inpatients. 
 
Antituberculosis therapy and pharmacokinetic study methods: 
Standard combination antituberculosis therapy for drug sensitive tuberculosis was 
administered according to weight as per the South African Department of Health 
National Tuberculosis Management guidelines [36] and consisted of four-drug fixed-
dose combination (FDC) tablets containing rifampicin (150 mg), isoniazid (75 mg), 
pyrazinamide (400 mg) and ethambutol (275 mg). In the first eight weeks of 
treatment, patients weighing 30 to 37 kg received two FDC tablets per dose, while 
those weighing 38 to 54, 55 to 70, or >70 kg received three, four, or five tablets 
respectively. One inpatient had crushed tablets (mixed with water) inserted via a 
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nasogastric tube. Two inpatients with renal impairment received separate rifampicin, 
isoniazid, pyrazinamide and ethambutol tablets to allow alternate day dosing of 
ethambutol. Patients received the FDC formulation in use at the hospital and clinic at 
the time the study was conducted. All outpatient controls and 31/59 (52.5%) of 
hospitalized patients received Rifafour e-275 (SANOFI) and the remaining 
hospitalized patients received RITIBTM (PHARMACARE LIMITED). 
Participants were fasted overnight and were offered a standardized breakfast after 
the 1-hour sample and a standardized lunch between the 4- and 6-hour sample. The 
study team administered the third dose of antituberculosis therapy and collected 
samples immediately before (0 hours) and at 1, 2.5, 4, 6 and 8 hours after the dose. 
Timing of samples were calculated from the time the dose was administered and all 
samples were collected within a 10-minute window (+/-5 minutes). A cold chain was 
maintained by placing blood samples in crushed ice immediately after collection, 
spinning in a cold centrifuge (8°C) and flash freezing plasma aliquots in dried ice 
within 30 minutes of collection. Plasma aliquots were transported and stored in a -
80°C freezer at the end of each day. 
Rifampicin, isoniazid and pyrazinamide concentrations were measured on stored 
plasma using high-performance liquid chromatography (HPLC) coupled to tandem 
mass spectrometry (MS) at the Division of Clinical Pharmacology Laboratory, 
University of Cape Town. The combined accuracy (%Nom) and precision (%CV) 
statistics of the low, medium, and high quality control samples during analysis (n = 
22) of the rifampicin assay were between 99.7% and 100.8%, and 4.7% and 7.7%, 
respectively. The combined accuracy (%Nom) and precision (%CV) statistics of the 
low, medium, and high quality control samples during analysis (n = 22) of the 
isoniazid assay were between 98.3% and 100.4%, and 3.0% and 5.1%, respectively. 
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The combined accuracy (%Nom) and precision (%CV) statistics of the low, medium, 
and high quality control samples during analysis (n = 22) of the pyrazinamide assay 
were between 88.1% and 92.3%, and 2.9% and 3.6%, respectively. Baseline blood 
tests including venous lactate measurements were performed at the National Health 
Laboratory Services.  
 
Ethical approval 
The study was approved by the University of Cape Town Human Research Ethics 
Committee (UCT HREC reference: 057/2013) and written informed consent was 
obtained for the pharmacokinetic sub-study. Eligible inpatients with a decreased 
level of consciousness were enrolled and followed up daily until they regained 
capacity to participate in the informed consent process. Permission was sought from 
the UCT HREC to use information of participants who died prior to providing 
informed consent. 
 
Statistical Analysis 
Non-compartmental analysis was performed using Stata/SE 13.1 for Mac 
(StataCorp, 4905 Lakeway Dr, College Station, Texas 77845 USA) and all other 
comparative statistics were performed and plots created using R version 3.4.4 and 
the R Studio interface version 1.0.143 [37 38]. Maximum concentration (Cmax) is 
defined as the maximum plasma concentration reached after administration of the 
third dose of antituberculosis therapy and within 8 hours. Comparisons between Cmax 
and area under the concentration-time curve from 0 to 8 hours (AUC0-8) were made 
between inpatients and outpatients; between inpatients who survived and those who 
died, and between inpatients presenting with elevated lactate concentrations and 
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those presenting with a normal lactate. We compared groups using the Wilcoxon 
rank sum, Kruskal Wallis, Pearson’s Chi squared or Fisher’s exact test, where 
appropriate and report median values with interquartile range (IQR) or number and 
percentage. We compared HIV positive outpatient controls to HIV negative 
outpatient controls. There were no differences in PK parameters of HIV positive 
versus HIV negative outpatients (Supplementary Table 5) and this group was not 
disaggregated for any of the other analyses. Lactate was also compared to 
pharmacokinetic variables as a continuous variable. Correlations were performed on 
log or square root transformed variables using Pearson’s correlation test or 
Spearman’s rank correlation where appropriate. In hospitalized patients we 
calculated the odds ratio for survival per doubling of lactate concentration using a 
logistic regression model and log2 transformed lactate concentration. We did not 
adjust for other clinical variables. We performed correlation tests (Pearson or 
Spearman’s correlation) to assess relationships between pharmacokinetic variables, 
creatinine clearance and conjugated bilirubin, and pyrazinamide exposure with two 
inflammatory markers (C-reactive protein and procalcitonin). Concentrations below 
the lower limit of quantification (LLQ) were imputed at half the value of the LLQ. 
Missing concentrations were imputed using the slope of the relevant drug’s log 
concentration curve for the patient when possible (Supplementary Table 1 and 2). 
The LLQ for rifampicin, isoniazid and pyrazinamide were 0.117 µg ml-1, 0.105 µg ml-
1and 0.203 µg ml-1, respectively. 
Drug concentrations were log-transformed and the geometric mean was calculated 
by exponentiating the mean of the log-transformed values. We used published 
reference ranges of drug concentrations which can be expected after administration 
of standard doses of antituberculosis therapy for comparison for comparison of our 
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Cmax results (8 µg ml-1 – 24 µg ml-1 for rifampicin, 3 µg ml-1 – 6 µg ml-1 for isoniazid 
and 20 µg ml-1 – 60 µg ml-1 for pyrazinamide) [39-41]. 
 
Results 
Outcomes of the parent study and baseline characteristics 
The parent study enrolled 576 hospitalized patients with HIV-TB and the 12-week 
mortality was 124/576 (22%) at a median of 12.5 days from enrolment [34]. 
Intensive pharmacokinetic studies were performed in a sub-group of 60 inpatients, 
and in 48 outpatients with tuberculosis. One inpatient was excluded due to a high 
CD4 count and an alternative diagnosis of mycetoma. We analysed data from 59 
inpatients and 48 outpatients (Figure 1). Outpatients included 19/48 (40%) HIV-
uninfected patients. The median CD4 counts for inpatients and HIV-infected 
outpatients were 58 cells μL-1 and 146 cells μL-1, respectively (Table 1). Twelve-
week mortality for inpatients was 11/59 (19%) with median days from PK study to 
death = 40 days (interquartile range= 8-60 days). One inpatient was lost to follow up 
after 2 months. 
On baseline blood tests there were significant differences between inpatients and 
outpatient controls, including significantly lower CD4 count, haemoglobin, creatinine 
clearance, albumin, and significantly higher liver enzymes and C-reactive protein in 
inpatients (Table 1). Inpatients and outpatients received similar doses (mg kg-1) of 
rifampicin, isoniazid and pyrazinamide and there was a similar distribution of patients 
in different weight categories (Table 1). There were fewer differences between 
hospitalized patients who died and those who survived 12 weeks of follow up 
(Supplementary Table 3).  
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Maximum concentrations (Cmax) 
Comparing hospitalized patients to outpatients, neither the median rifampicin Cmax 
(7.4 μg mL-1 vs 8.3 μg mL-1, p = 0.223), nor the median isoniazid Cmax (3.6 μg mL-1 
vs 3.5 μg mL-1, p = 0.569) were significantly different. The median pyrazinamide Cmax 
in hospitalized patients was higher than outpatients (50.1 μg mL-1 vs 46.8 μg mL-1, 
p=0.081) but this did not reach statistical significance (Table 2 and Figure 2). 
Rifampicin Cmax was below the minimum threshold of the reference range of 8 μg 
mL-1 in 36/59 (62%) and 21/48 (44%), of hospitalized patients and outpatients (95% 
confidence interval of the difference in proportions (95% CI: -3.4; 37.9, p=0.079)), 
respectively. Isoniazid Cmax was below the minimum recommended 3 μg mL-1 in 
23/59 (39%) and 17/48 (35%) of hospitalized and outpatients respectively, 95% CI: -
16.7; 23.8, p=0.841. No pyrazinamide Cmax below the minimum reference range of 
20 μg mL-1 were observed. 
Comparing hospitalized patients who survived to those who died within 12 weeks, 
there were no significant differences in the median Cmax for rifampicin (7.2 μg mL-1 
versus 7.5 μg mL-1, p=0.655), isoniazid (3.9 μg mL-1 versus 3.2 μg mL-1, p=0.394) or 
pyrazinamide (48.0 μg mL-1 versus 55.1 μg mL-1, p=0.302) (Table 3 and Figure 2). 
Comparing inpatients who survived to those who died, there was no difference in the 
proportion with low rifampicin Cmax 29/47 (62%) versus 7/11 (64%, 95%CI: -35.5; 
31.6, p=1.000) and low isoniazid Cmax 18/47 (38%) versus 5/11 (46%, 95%CI: -45.3; 
31.0, p=0.738) (Figure 2 and Table 2).  
 
Area under the curve (AUC0-8) 
Comparing hospitalized patients to outpatients, the AUC0-8 for rifampicin (41.0 mg·h 
L-1 versus 43.8 mg·h L-1, p= 0.290), isoniazid (13.5 mg·h L-1 versus 12.4 mg·h L-1, 
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p=0.630) and pyrazinamide (316.5 mg·h L-1 versus 292.2 mg·h L-1, p=0.164) were 
not significantly different (Table 2 and Figure 3). 
Hospitalized patients who survived and those who died within 12 weeks had similar 
AUC0-8 for rifampicin (40.0 mg·h L-1 versus 43.2 mg·h L-1, p= 0.684), isoniazid (13.4 
mg·h L-1 versus 13.7 mg·h L-1, p= 0.976) and pyrazinamide (310.9 mg·h L-1 versus 
356.1 mg·h L-1, p= 0.128) (Table 3 and Figure 3). 
 
Patients presenting with an elevated lactate concentration 
In hospitalized patients, venous lactate was performed at enrolment in 58/59 (98%) 
patients. One patient who survived did not have lactate performed. 
Lactate was elevated (>2.2 mmol L-1) at presentation in 16/59 (27%). The median 
lactate for all inpatients was 1.6 mmol L-1, and the median was 1.45 mmol L-1 in 
patients who survived versus 2.4 mmol L-1 in patients who died, p = 0.078 
(Supplementary Table 3). The odds of survival decreased by 60% with doubling of 
the lactate concentration (odds ratio for survival per doubling of lactate: 0.41, 95%CI 
= 0.14 - 1.08, p = 0.078). The proportion of patients presenting with an elevated 
lactate was 10/47 (21%) in survivors and 6/11 (55%, 95%CI: -4.0; 70.5, p = 0.079) in 
patients who died.  
Comparing clinical characteristics of patients presenting with an elevated lactate to 
patients with normal lactate, patients with elevated lactate had significantly higher 
random glucose (Supplementary Table 4). Lactate concentration was positively 
correlated with random glucose and conjugated bilirubin concentrations 
(Supplementary Table 4). Lactate concentration was positively correlated with 
rifampicin Cmax and AUC0-8 with Spearman’s rho of 0.329, p = 0.012 and 0.376, 
p=0.004 respectively (Figure 4 and Table 4). Patients with an elevated lactate at 
 
This article is protected by copyright. All rights reserved. 
presentation (>2.2 mmol L-1) had significantly higher rifampicin Cmax (median = 9.0 
μg mL-1 versus 6.5 μg mL-1, p=0.002) and AUC0-8 (median = 47.3 mg·h L-1 versus 
36.7 mg·h L-1, p= 0.006) (Table 4) with a non-significant trend towards higher 
isoniazid and pyrazinamide Cmax and AUC0-8 (Table 4). These findings are contrary 
to our hypothesis that patients presenting with elevated lactate would have lower 
exposure to TB drugs. 
 
Associations of PK findings with selected clinical variables: 
Based on findings from previous studies and the physicochemical properties of the 
drugs we measured, we next performed an exploratory analysis to assess the 
relationship of selected clinical variables with our findings. In hospitalized patients we 
explored the correlations of pharmacokinetic variables with creatinine clearance and 
conjugated bilirubin concentrations. The only significant findings were a positive 
correlation of rifampicin AUC0-8 and Cmax with creatinine clearance (Pearson’s 
correlation coefficient [r] = 0.27, p= 0.040 and r = 0.29, p= 0.025 respectively) and a 
positive correlation of rifampicin AUC0-8 with conjugated bilirubin concentration (r = 
0.38, p = 0.004). Rifampicin Cmax and conjugated bilirubin showed a positive trend, r 
= 0.26, p=0.055. (Supplementary Figure 1). 
Pyrazinamide exposure was not correlated with C-reactive protein (AUC0-8: r = 0.02, 
p = 0.839, Cmax: r = 0.01, p = 0.885) or procalcitonin concentrations (AUC0-8: r = -
0.01, p = 0.947, Cmax: r = 0.07, p = 0.585). 
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Discussion 
We measured concentrations of rifampicin, isoniazid and pyrazinamide on the third 
day of antituberculosis therapy in hospitalized adults with a new diagnosis of HIV-
associated tuberculosis and in outpatient controls. We found high 12-week mortality 
of 19% for inpatients and no significant difference in Cmax or AUC0-8 of rifampicin, 
isoniazid, or pyrazinamide between hospitalized patients and outpatients, or between 
hospitalized patients who survived and those who died. Rifampicin and isoniazid 
peak concentrations were below reference ranges in 61% and 39% of inpatients and 
44% and 35% of outpatients. All patients attained pyrazinamide concentrations 
within the reference range. We found significantly higher rifampicin Cmax and AUC0-8 
amongst patients presenting with elevated venous lactate, taken as a marker of 
sepsis severity. 
We observed high 12-week mortality despite treatment and patients died at a median 
of 40 days after the PK study. This time to death is longer than the median days to 
death in the main study which was 12.5 days from enrolment [34]. This PK study was 
performed within the routine clinical service. Critically ill patients requiring intensive 
care were transferred to a tertiary facility or died and stable patients were often 
discharged before the third day of antituberculosis therapy and could thus not be 
included in the PK study. 
A large proportion of all patients had sub-optimal rifampicin and isoniazid peak 
concentrations. Low concentrations of antituberculosis medications have been 
reported in other studies [29 42] and low exposure to especially pyrazinamide have 
been associated with poor clinical outcomes. One study conducted intensive PK 
studies at 2 months on treatment and monitored 2-year outcomes in South African 
pulmonary tuberculosis patients [31]. They used classification and regression tree 
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(CART) analysis which identified pyrazinamide AUC0-24 below 363 mg·h L-1 as the 
highest-ranking factor associated with poor 2-year outcomes (relapse, death or 
therapy failure). A predominantly HIV-infected pulmonary tuberculosis cohort from 
Botswana had PK studies performed after at least seven days on treatment and 
were followed for the duration of treatment. Lower peak concentrations of 
pyrazinamide (<35 μg mL-1) was the only pharmacokinetic variable associated with 
poor outcome and was associated with 3-fold increased risk of poor outcome [29]. In 
our cohort, pyrazinamide Cmax was <35 μg mL-1 in six patients (5 inpatients who 
survived and 1 outpatient) and there was a trend towards higher exposure in 
hospitalized patients. One potential mechanism for a trend towards higher 
pyrazinamide AUC0-8 in inpatients who died is impaired renal clearance due to acute 
kidney injury. Pyrazinamide and its main metabolite pyrazinoic acid are excreted in 
the urine [43] and although hospitalized patients and specifically inpatients who died 
had higher creatinine, we observed no significant correlation between pyrazinamide 
exposure and creatinine clearance. Pyrazinamide clearance was shown to be 
inversely correlated to chronic cellular immune activation in HIV-TB patients in 
Botswana [44]. We did not measure HLA-DR expression on CD8 T cells in our study, 
and even though hospitalized patients and specifically patients who died had higher 
C-reactive protein and procalcitonin, there was no significant correlation between 
pyrazinamide exposure and either of these markers. 
In a previous study optimal early bactericidal activity was associated with an 
isoniazid Cmax and AUC0-∞   of more than 2.19 μg ml-1 and 10.52 mg·h L-1, 
respectively. In our study 10/59 (17%) and 23/59 (40%) of hospitalized patients had 
isoniazid Cmax and AUC0-8 below these values respectively. Optimal early bactericidal 
effect may be important for survival in this patient group. 
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In hospitalized patients we found a median rifampicin AUC0-8 of 41.0 mg·h L-1 which 
is higher than the predicted AUC0-24 (30.7 mg·h L-1) previously reported in South 
African pulmonary tuberculosis patients and HIV-infected pulmonary tuberculosis 
patients in Botswana at steady state (36.3 mg·h L-1 and 34.4 mg·h L-1) [42 45 46]. 
Higher AUC0-8 values in our study are expected because auto-induction with the 
resulting drop in AUC value takes four weeks [47 48] and would not have been 
complete at this early therapeutic time point (3 days). 
We found significantly higher Cmax and AUC0-8 for rifampicin in inpatients presenting 
with elevated lactate, which is contrary to our hypothesis, and a positive correlation 
of rifampicin Cmax and AUC0-8 with conjugated bilirubin. Lactate is used as a marker 
of sepsis severity and likely reflects increased aerobic glycolysis on cellular level due 
to adrenergic stimulation [49] and metabolic switching of activated innate immune 
cells to aerobic glycolysis in critically ill patients [50 51]. The largest proportion of 
tissue resident macrophages (Kupffer cells) are present in the liver and these cells 
play a critical role in the innate immune response to pathogens, which involves 
activation and metabolic switch to a pro-inflammatory (M1-macrophage) phenotype 
and have important anti-microbial activity [52]. Rifampicin and its active metabolite 
desacetylrifampicin are lipid soluble, have enterohepatic circulation, competes with 
bilirubin for biliary excretion and are excreted mainly in bile and but also in urine [32]. 
High pre-treatment bilirubin levels in patients with advanced liver cirrhosis are 
associated with higher rifampicin exposure [53]. It is possible that the cellular 
metabolic changes which underly higher lactate concentrations could play a role in 
the higher rifampicin exposure we observed in these patients. Neither of the 
hydrophylic drugs (isoniazid or pyrazinamide) were correlated with creatinine 
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clearance, but rifampicin exposure was positively correlated with creatinine 
clearance. The mechanism for this is unclear. 
One third of hospitalized patients in this cohort had MTB blood stream infection, 
however inpatients achieved concentrations and exposures similar to ambulant 
outpatients. The high mortality amongst hospitalized patients and the high proportion 
with maximum concentrations below minimum thresholds of reference ranges 
suggest that these concentrations and exposures may not be adequate in critically ill 
patients. 
The parent study demonstrated an association between mortality and a higher 
number of mycobacterial dissemination markers being positive as well as an immune 
profile dominated by innate mediators [34]. These findings together with our findings 
of sub-optimal rifampicin and isoniazid concentrations in hospitalized HIV-TB 
patients provide directions to consider for improving treatment strategies. One 
objective of treatment optimization studies should be to evaluate if more rapid 
reduction of disseminated mycobacterial infection load can be achieved and whether 
this improves survival. Strategies to accomplish this could include higher dose 
rifampicin, higher dose isoniazid or the addition of another rapidly bactericidal drug 
such as a fluoroquinolone. The safety and efficacy of these strategies would need to 
be tested in clinical trials in this patient population. Other strategies to evaluate could 
include those that modulate the immune response associated with mortality. 
Treatment optimization research in hospitalized HIV-TB patients should consider and 
could draw on the experience of treatment optimization research in the field of 
tuberculous meningitis, in particular findings regarding the efficacy and safety of 
higher dose rifampicin and isoniazid [54]. 
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Strengths of this study are that we performed intensive PK sampling in acutely ill 
hospitalized patients in a routine care setting at an early therapeutic time point and in 
a control group with pulmonary tuberculosis from the same geographical area at the 
same therapeutic time point. These results could help to inform future treatment 
optimization strategies in hospitalized HIV-TB patients. The study has several 
limitations, firstly performing the PK studies on the third day of antituberculosis 
therapy likely introduced survival bias because some critically ill patients were 
transferred or died before the third day of antituberculosis therapy. Half of the 
hospitalized patients received a FDC combination from a different manufacturer and 
this may have introduced variation in the drug concentrations. We did not calculate 
AUC0-24h and reported only AUC0-8h. We did not perform genotyping to assess 
patients’ isoniazid acetylator status. Potential unmeasured differences in distribution 
of acetylator status across the comparator groups may have biased our analysis of 
the PK of isoniazid. The associations of pharmacokinetic variables with selected 
clinical variables could be due to other underlying mechanisms than the potential 
mechanisms we explored. 
 
In conclusion, rifampicin and isoniazid peak concentrations were below reference 
ranges in 62% and 39% of hospitalized patients with HIV-associated tuberculosis. 
Isoniazid peak concentration and exposure were below the levels associated with 
optimal early bactericidal activity in 17% and 40% of inpatients. Inadequate exposure 
to key antituberculosis drugs during initial therapy may contribute to the high 
mortality observed in acutely ill patients hospitalized with HIV-TB. While upstream 
public health interventions are needed to prevent diagnostic and treatment delays, 
TB treatment strategies in patients hospitalized with HIV-TB need to be optimized to 
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improve survival. Novel therapeutic strategies should be evaluated for safety and 
efficacy in this patient population. 
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Table 1: Baseline characteristics of outpatient controls with tuberculosis and 
hospitalized patients with HIV-associated tuberculosis who had intensive 
pharmacokinetic studies performed on the third day of antituberculosis 
therapy 
 
Outpatient Controls 
n=48 
Hospitalized  
n=59 
p 
First episode of TB 32 (71.1) 35 (59.3) 0.286 
Sex, Male 36 (75.0) 28 (47.5) 0.005 
Age, years  36 [32, 42] 37 [32, 41] 0.980 
HIV infected 29 (60.4) 59 (100) - 
aHIV viral load, log copies ml-1 5.4 [4.3, 5.5] 5.0 [3.3, 5.7] 0.684 
bCD4 count, cells μL-1  146 [37, 233] 53 [16, 129] 0.007 
cCurrent antiretroviral therapy 5 (17.2) 20 (34.5) 0.169 
dMTB on TB blood culture - 16 (28.1) - 
Glasgow coma score <15 at presentation 0 (0.0) 12 (20.3) 0.003 
eHeight, meters  1.69 [1.64, 1.75] 1.64 [1.59, 1.70] 0.002 
Weight, kilograms 57.2 [52.0, 62.3] 54.5 [48.0, 60.8] 0.039 
fBody mass index  19.6 [18.3, 21.8] 19.3 [17.6, 22.4] 0.561 
Body mass index <18.5 kg per m2 15 (31.2) 21 (41.2) 
0.681 Body mass index 18.5 – 24.9 kg per m2 29 (60.4) 26 (51.0) 
Body mass index >25 kg per m2 4 (8.3) 4 (6.8) 
Random glucose, mmol L-1 4.5 [4.1, 5.2] 5.2 [4.7, 5.9] 0.002 
Lactate, mmol L-1  - 1.6 [1.1, 2.3] - 
C-reactive protein, mg L-1  78.5 [46.8, 134.5] 192.0 [105.1, 264.5] <0.001 
Procalcitonin, μg mL-1 - 3.7 [0.6, 17.2] - 
Aspartate amino transferase, U L-1 29.0 [21.0, 49.8] 50.0 [34.0, 82.3] <0.001 
Alanine amino transferase, U L-1  19.5 [13.0, 29.0] 27.0 [18.0, 47.0] 0.012 
Gamma-glutamyl transferase, U L-1 49.5 [35.8, 93.3] 77.0 [46.5, 144.5] 0.005 
Alkaline phosphatase, U L-1  88.0 [74.0, 117.5] 106.0 [75.5, 154.3] 0.043 
Total bilirubin, μmol L-1 10.0 [6.8, 14.0] 10.00 [6.0, 14.5] 0.967 
Conjugated bilirubin, μmol L-1 6.0 [4.0, 8.0] 6.0 [3.0, 9.0] 0.607 
Total protein, g L-1  81.0 [75.0, 87.5] 80.0 [69.5, 85.0] 0.068 
Albumin, g L-1   33.5 [32.0, 37.0] 25.0 [21.0, 29.5] <0.001 
Creatinine, μmol L-1  62.0 [51.50, 72.5] 95.0 [63.0, 142.0] <0.001 
Creatinine clearance, mL minute-1 120.5 [96.9, 145.7] 68.2 [45.2, 96.1] <0.001 
Haemoglobin, g dL-1  11.1 [9.6, 12.0] 8.7 [7.1, 9.9] <0.001 
White cell count, x109 L-1  7.1 [5.7, 9.6] 7.2 [5.1, 9.8] 0.770 
Platelets, x109 L-1  424.0 [316.0, 505.0] 291.0 [199.0, 355.0] <0.001 
Absolute neutrophil count, x109 L-1  4.80 [3.53, 6.91] 5.43 [3.58, 8.41] 0.241 
Absolute lymphocyte count, x109 L-1  1.36 [1.04, 1.82] 0.66 [0.36, 0.95] <0.001 
Absolute monocyte count, x109L-1  0.69 [0.50, 0.83] 0.34 [0.18, 0.62] <0.001 
Rifampicin dose, mg kg-1 10.3 [9.2 - 10.9] 10.0 [9.2, 11.1] 0.607 
Isoniazid dose, mg kg-1 5.2 [4.6 - 5.5] 5.0 [4.6, 5.6] 0.754 
Pyrazinamide dose, mg kg-1 27.6 [24.4 - 29.1] 26.7 [24.4, 29.6] 0.525 
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Continuous variables are presented as median with interquartile range and 
categorical variables as number with percentage. 
p-value represents result of the non-parametric test comparison (Wilcoxon rank sum 
test for continuous variables and Fisher’s exact or Pearson’s Chi squared test for 
categorical variables).  
TB: Tuberculosis; HIV: Human immunodeficiency virus; CD4: Cluster of 
differentiation 4; MTB: Mycobacterium tuberculosis 
aHIV viral load for hospitalized patients (n=59) and HIV-infected outpatients (n=29) 
bCD4 count for all hospitalized patients (n=59) and HIV-infected outpatients (n=29) 
cCurrent antiretroviral therapy indicated as a proportion of HIV-infected outpatients 
(n=29). 
dMycobacterial blood culture was not performed in outpatients. 
eHeight was missing for 8 hospitalized patients: 4 survivors, 3 patients who died, 1 
lost to follow up. 
fBody mass index was not calculated for patients with missing height. 
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Table 2: Rifampicin, isoniazid and pyrazinamide area under the concentration 
curve (0-8 hours) and maximum concentration: Comparison of outpatient 
controls and hospitalized patients with HIV-associated tuberculosis. 
 
Drug PK parameter 
Outpatient Controls 
n=48 
Hospitalized  
n=59 
p 
Rifampicin 
aAUC 43.8 [35.3, 53.8] 41.0 [28.3, 49.7] 0.290 
bAUC 41.4 (1.5) 37.2 (1.8) 0.291 
Cmax 8.3 [6.8, 9.5] 7.4 [6.1, 9.3] 0.223 
Low Cmax 21 (43.8)  36 (62.1) 0.079 
Isoniazid 
aAUC 12.4 [8.6, 18.9] 13.5 [8.9, 18.7] 0.630 
bAUC 12.5 (1.6) 13.1 (1.7) 0.632 
Cmax 3.5 [2.4, 4.5] 3.6 [2.6, 5.0] 0.569 
Low Cmax 17 (35.4) 23 (39.0) 0.841 
Pyrazinamide 
aAUC 292.2 [272.2, 319.3] 316.5 [255.4, 359.1] 0.164 
bAUC 291.6 (1.8) 311.8 (1.3) 0.165 
Cmax 46.8 (41.9, 51.1) 50.1 [44.1, 58.4] 0.081 
Low Cmax 0 (0.0)  0 (0.0)  - 
 
PK: Pharmacokinetic; n= number 
aAUC: Area under the concentration curve: 0 – 8 hours in mg·h L-1: Median and 
interquartile range are presented. 
bAUC: Area under the concentration curve: 0 – 8 hours in mg·h L-1: Geometric mean 
and geometric standard deviation (approximate coefficient of variation) are 
presented. 
Cmax: Maximum concentration in μg ml-1: Median and interquartile range are 
presented. 
Low Cmax: Number and percentage of patients with maximum concentrations below 
minimum threshold of reference ranges: 8 μg mL-1 for rifampicin, 3 μg mL-1 for 
isoniazid and 20 μg mL-1 for pyrazinamide (reference: Alsultan A, Peloquin CA. 
Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 
2014;74(8):839-54).  
P value represents the result of the non-parametric comparison (Wilcoxon rank sum 
test) for the numerical values or the Pearson’s Chi squared test for categorical 
variables, comparing outpatient controls to hospitalized patients with HIV-associated 
tuberculosis. 
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Table 3: Rifampicin, isoniazid and pyrazinamide area under the concentration 
curve (0-8 hours) and maximum concentration: Comparison of hospitalized 
patients with HIV-associated tuberculosis who survived or died within 12 
weeks. 
 
Patients were followed up for 12 weeks to ascertain vital status. One patient was lost 
to follow up at 2 months and is not included in this table. 
PK: Pharmacokinetic; n= number 
aAUC: Area under the concentration curve: 0 – 8 hours in mg·h L-1: Median and 
interquartile range are presented. 
bAUC: Area under the concentration curve: 0 – 8 hours in mg·h L-1: Geometric mean 
and geometric standard deviation (approximate coefficient of variation) are 
presented. 
Cmax: Maximum concentration in μg ml-1: Median and interquartile range are 
presented. 
Low Cmax: Number and percentage of patients with maximum concentrations below  
minimum threshold of reference ranges: 8 μg mL-1 for rifampicin, 3 μg mL-1 for 
isoniazid and 20 μg mL-1 for pyrazinamide (reference: Alsultan A, Peloquin CA. 
Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 
2014;74(8):839-54).  
P value represents the result of the non-parametric comparison (Wilcoxon rank sum 
test) for the numerical values or the Pearson’s Chi squared test for categorical 
variables, comparing hospitalized patients with HIV-associated tuberculosis who 
survived the 12-weeks and those who died within 12 weeks. 
  
Drug PK parameter 
Hospitalized Survivors 
n=47 
Hospitalized Deaths 
n=11 
p 
Rifampicin 
1AUC 40.0 [27.8, 49.0] 43.2 (30.7, 49.4] 0.684 
2AUC 35.5 (1.8) 41.5 (1.7) 0.696 
Cmax 7.2 [6.1, 9.2] 7.5 [6.5, 9.1] 0.655 
Low Cmax 29 (61.7)  7 (63.6)  1.000 
Isoniazid 
1AUC 13.4 [9.0, 18.4] 13.7 [7.1, 22.5] 0.976 
2AUC 13.1 (1.7) 13.0 (2.0) 0.984 
Cmax 3.9 [2.8, 5.0] 3.2 [2.5, 4.1] 0.394 
Low Cmax 18 (38.1)  5 (45.5)  0.738 
Pyrazinamide 
1AUC 310.9 [251.1, 354.2] 356.1 [293.0, 437.1] 0.124 
2AUC 303.8 (1.3) 359.3 (1.4) 0.128 
Cmax 48.0 [44.4, 57.6] 55.1 [45.0, 63.4] 0.302 
Low Cmax 0 (0.0)   0 (0.0)  - 
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Table 4: Rifampicin, isoniazid and pyrazinamide area under the concentration 
curve (0-8 hours) and maximum concentration: Comparison of patients 
presenting with normal lactate and with high lactate concentrations. 
 
 
Lactate is used as a marker of sepsis severity and we divided patients into those 
presenting with high lactate (>2.2 mmol L-1, n=16) and those presenting with normal 
lactate (n=41) concentration. One patient who survived had no lactate performed and 
is not included in this table.  
Pharmacokinetic parameters were compared between groups using a non-
parametric comparison (Wilcoxon rank sum test) for the numerical values or the 
Pearson’s Chi squared test for categorical variables. 
In addition, lactate was treated as a continuous variable and correlation tests 
(Spearman’s rank correlation (distribution not normal) or Pearson’s correlation test 
(normal distribution)) were used to correlate lactate concentrations with 
pharmacokinetic variables.  
PK: Pharmacokinetic; n= number 
aAUC: Area under the concentration curve: 0 – 8 hours in mg·h L-1: Median and 
interquartile range are presented. 
bAUC: Area under the concentration curve: 0 – 8 hours in mg·h L-1: Geometric mean 
and geometric standard deviation (approximate coefficient of variation) are 
presented. 
Cmax: Maximum concentration in μg ml-1: Median and interquartile range are 
presented. 
Low Cmax: Number and percentage of patients with maximum concentrations below 
minimum threshold of reference ranges: 8 μg mL-1 for rifampicin, 3 μg mL-1 for 
isoniazid and 20 μg mL-1 for pyrazinamide (reference: Alsultan A, Peloquin CA. 
Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 
2014;74(8):839-54).  
Correlation coefficient: Spearman’s rho or Pearson’s correlation coefficient. 
 
  
Drug 
PK 
parameter 
Normal lactate 
n=42 
High lactate 
n=16 
1p 
Correlation 
coefficient 
2p 
Rifampicin 
aAUC 36.7 [24.0, 47.8] 47.3 [43.0, 63.4] 0.006 0.376 0.004 
bAUC 32.9 (1.8) 50.6 (1.5) 0.003 - - 
Cmax 6.6 [5.6, 8.3] 9.0 [7.5, 14.4] 0.002 0.329 0.012 
Low Cmax 29 (70.7) 7 (43.8) 0.073 - - 
Isoniazid 
aAUC 13.2 [8.4, 17.8] 16.6 [9.7, 25.1] 0.244 0.144 0.281 
bAUC 12.6 (1.7) 15.2 (1.8) 0.250 - - 
Cmax 3.6 [2.6, 5.0] 4.1 [2.7, 5.2] 0.424 0.096 0.474 
Low Cmax 16 (38.1) 6 (37.5) 1.000 - - 
Pyrazinamide 
aAUC 302.9 [234.7, 359.7] 333.1 [285.9, 369.2] 0.117 0.162 0.224 
bAUC 299.5 (1.3) 344.8 (1.3) 0.120 - - 
Cmax 47.4 [41.8, 57.6] 54.1 [47.2, 63.1] 0.073 0.179 0.180 
Low Cmax 0 (0.0)  0 (0.0)  - - - 
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Figure 1: Study flow chart: 
Hospitalized HIV-infected adults with a CD4 count of ≤350 cells μl-1 starting 
tuberculosis treatment in hospital and ambulant outpatients (HIV-infected and 
uninfected) were enrolled for intensive pharmacokinetic studies. Inpatients were 
enrolled at presentation and PK studies were performed within the routine hospital 
service on the third day of antituberculosis therapy, provided they still required 
inpatient care and did not need transfer for intensive care. Outpatients were enrolled 
at treatment initiation and returned for PK studies on the third day of therapy. Twelve-
week mortality was ascertained for inpatients. 
*Exclusions are only listed if participants had consented to take part in the study and 
PK study could not be performed. We did not document all patients who qualified to 
take part in the PK study and could not be included due to logistical reasons such as 
early deaths, transfers to tertiary facilities and staff availability. 
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Figure 2: Rifampicin, isoniazid and pyrazinamide peak concentrations (Cmax) on the third day of antituberculosis therapy: 
Boxplots of rifampicin, isoniazid and pyrazinamide maximum concentrations are presented in μg ml-1 for outpatients (green), 
hospitalized patients who survived 12 week follow up (blue) and hospitalized patients who died within 12 weeks (black).  
P value: Kruskal-Wallis test comparing Cmax values across three groups. 
Dashed horizontal lines represent the minimum threshold of the reference range: 8 μg ml-1 for rifampicin, 3 μg ml-1 for isoniazid and 
20 μg ml-1 for pyrazinamide. 
Cmax: Maximum (peak) concentration; Outpatients: Ambulant tuberculosis patients attending outpatient clinic for treatment; 
Hosp.Survivors: Hospitalized survivors; Hosp.Deaths: Hospitalized patients who died within 12 weeks of enrolment.  
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Figure 3: Rifampicin, isoniazid and pyrazinamide area under the curve (0-8 hours) on the third day of antituberculosis 
therapy: 
Boxplots of rifampicin, isoniazid and pyrazinamide area under the concentration curve (0-8 hours) presented in mg·h L-1 for 
outpatients (green), hospitalized patients who survived 12 week follow up (blue) and hospitalized patients who died within 12 weeks 
(black).  
P value: Kruskal-Wallis test comparing AUC(0-8) values across three groups. 
AUC (0-8 hours): area under the concentration curve from zero to eight hours; Outpatients: Ambulant tuberculosis patients attending 
outpatient clinic for treatment; Hosp.Survivors: Hospitalized survivors; Hosp.Deaths: Hospitalized patients who died within 12 weeks 
of enrolment.  
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Figure 4: Rifampicin peak concentrations (Cmax) and area under the curve (AUC0-8) on the third day of antituberculosis 
therapy compared with lactate concentration at presentation. 
Rifampicin exposure was compared to lactate concentration, a marker of sepsis severity, at presentation.  
Rifampicin maximum concentration and area under the concentration time curve (AUC0-8) was first correlated with lactate 
concentration at presentation (panel A and B). The blue line indicates the linear regression line of best fit. The blue dots indicate 
patients who survived to 12 weeks, the black dots indicate patients who died within twelve weeks and the green dot indicates one 
patient who was lost to follow up at 8 weeks.  
Panel C and D are boxplots comparing rifampicin concentration in μg ml-1 between hospitalized patients who presented with a normal 
lactate concentration to those presenting with high lactate (>2.2 mmol L-1) concentrations. 
r: Result of Spearman’s rank correlation test in panel A and Pearson’s correlation coefficient in panel B. 
Cmax: Maximum (peak) concentration; Sqrt: square root transformed; log: log transformed; normal.lactate: patients presenting with 
normal lactate concentrations; high.lactate: patients presenting with high lactate (>2.2 mmol L-1). 
 
 
